Israel Englander’s Minerva Neurosciences NERV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.96M | Sell |
533,602
-174,689
| -25% | -$947K | ﹤0.01% | 3487 |
|
|
2026
Q1 | $4.27M | Buy |
708,291
+570,380
| +414% | +$3.27M | ﹤0.01% | 3129 |
|
|
2025
Q4 | $554K | Buy |
+137,911
| New | +$512K | ﹤0.01% | 4877 |
|
|
2023
Q1 | – | Sell |
-28,881
| Closed | -$46K | – | 6682 |
|
|
2022
Q4 | $46K | Buy |
28,881
+321
| +1% | +$1.39K | ﹤0.01% | 5802 |
|
|
2022
Q3 | $264K | Sell |
28,560
-51,076
| -64% | -$303K | ﹤0.01% | 5466 |
|
|
2022
Q2 | $264K | Sell |
79,636
-18,874
| -19% | -$77.1K | ﹤0.01% | 5465 |
|
|
2022
Q1 | $654K | Sell |
98,510
-1,415
| -1% | -$8.68K | ﹤0.01% | 4903 |
|
|
2021
Q4 | $640K | Buy |
99,925
+2,497
| +3% | +$23.5K | ﹤0.01% | 4830 |
|
|
2021
Q3 | $1.36M | Sell |
97,428
-64,378
| -40% | -$968K | ﹤0.01% | 4350 |
|
|
2021
Q2 | $3M | Buy |
161,806
+90,356
| +126% | +$1.94M | ﹤0.01% | 3437 |
|
|
2021
Q1 | $1.67M | Buy |
71,450
+20,632
| +41% | +$516K | ﹤0.01% | 3705 |
|
|
2020
Q4 | $951K | Buy |
50,818
+40,791
| +407% | +$1.03M | ﹤0.01% | 3777 |
|
|
2020
Q3 | $255 | Buy |
10,027
+6,805
| +211% | +$184K | ﹤0.01% | 3941 |
|
|
2020
Q2 | $93K | Sell |
3,222
-92,221
| -97% | -$5.41M | ﹤0.01% | 3984 |
|
|
2020
Q1 | $4.6M | Sell |
95,443
-6,734
| -7% | -$406K | 0.01% | 1387 |
|
|
2019
Q4 | $5.81M | Buy |
102,177
+20,355
| +25% | +$898K | 0.01% | 1806 |
|
|
2019
Q3 | $5.07M | Sell |
81,822
-16,789
| -17% | -$951K | 0.01% | 1797 |
|
|
2019
Q2 | $4.44M | Sell |
98,611
-16,705
| -14% | -$836K | 0.01% | 1868 |
|
|
2019
Q1 | $7.25M | Sell |
115,316
-41,144
| -26% | -$2.47M | 0.01% | 1506 |
|
|
2018
Q4 | $8.44M | Buy |
156,460
+8,732
| +6% | +$639K | 0.01% | 1231 |
|
|
2018
Q3 | $14.8M | Buy |
147,728
+32,794
| +29% | +$2.46M | 0.02% | 1032 |
|
|
2018
Q2 | $7.59M | Buy |
114,934
+3,137
| +3% | +$191K | 0.01% | 1508 |
|
|
2018
Q1 | $5.59M | Buy |
111,797
+87,152
| +354% | +$4.19M | 0.01% | 1727 |
|
|
2017
Q4 | $1.19M | Sell |
24,645
-6,483
| -21% | -$321K | ﹤0.01% | 2588 |
|
|
2017
Q3 | $1.89M | Buy |
31,128
+23,832
| +327% | +$1.37M | ﹤0.01% | 2198 |
|
|
2017
Q2 | $517K | Sell |
7,296
-2,162
| -23% | -$140K | ﹤0.01% | 2785 |
|
|
2017
Q1 | $613K | Sell |
9,458
-57,554
| -86% | -$4.47M | ﹤0.01% | 2701 |
|
|
2016
Q4 | $6.3M | Sell |
67,012
-40,066
| -37% | -$4.09M | 0.01% | 1181 |
|
|
2016
Q3 | $12.1M | Buy |
107,078
+3,255
| +3% | +$316K | 0.02% | 821 |
|
|
2016
Q2 | $8.48M | Buy |
103,823
+100,803
| +3,338% | +$6.41M | 0.02% | 952 |
|
|
2016
Q1 | $148K | Buy |
+3,020
| New | +$129K | ﹤0.01% | 3019 |
|
|
2014
Q4 | – | Sell |
-1,890
| Closed | -$91K | – | 4164 |
|
|
2014
Q3 | $91K | Buy |
+1,890
| New | +$100K | ﹤0.01% | 3563 |
|
Other funds holding NERV
JT
VC
LGM
FCM
ABG
FCMV
Israel Englander's NERV Position: Q2 2026 in Review
Israel Englander reduced its Minerva Neurosciences (NERV) stake by 25% in Q2 2026, selling an estimated $947K and leaving 533,602 shares worth $2.96M. The position accounts for ﹤0.01% of the portfolio, ranked #3487.
Israel Englander first reported a position in NERV in Q3 2014 and has held it in 32 quarters since. The position peaked at $14.8M in Q3 2018. 60 funds tracked by Wall St. Rank hold NERV as of Q2 2026.
- Israel Englander held 533,602 shares of Minerva Neurosciences worth $2.96M as of Q2 2026.
- Israel Englander sold 174,689 Minerva Neurosciences shares in Q2 2026, an estimated $947K.
- Minerva Neurosciences made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #3487 holding.
- Israel Englander first reported a position in Minerva Neurosciences in Q3 2014 and has held it in 32 quarters since.
- Israel Englander's Minerva Neurosciences position peaked at $14.8M in Q3 2018.
- 60 funds tracked by Wall St. Rank held Minerva Neurosciences as of Q2 2026.
Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.